- Home
- AARD vs RGCO Comparison
AARD vs RGCO Comparison
Compare AARD & RGCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AARD
- RGCO
- Stock Information
- Founded
- AARD 2017
- RGCO 1912
- Country
- AARD United States
- RGCO United States
- Employees
- AARD N/A
- RGCO N/A
- Industry
- AARD Biotechnology: Pharmaceutical Preparations
- RGCO Oil & Gas Production
- Sector
- AARD Health Care
- RGCO Utilities
- Exchange
- AARD Nasdaq
- RGCO Nasdaq
- Market Cap
- AARD 186.3M
- RGCO 221.2M
- IPO Year
- AARD 2025
- RGCO N/A
- Fundamental
- Price
- AARD $16.08
- RGCO $21.64
- Analyst Decision
- AARD Strong Buy
- RGCO
- Analyst Count
- AARD 7
- RGCO 0
- Target Price
- AARD $31.43
- RGCO N/A
- AVG Volume (30 Days)
- AARD 238.4K
- RGCO 14.2K
- Earning Date
- AARD 11-14-2025
- RGCO 11-12-2025
- Dividend Yield
- AARD N/A
- RGCO 3.80%
- EPS Growth
- AARD N/A
- RGCO 5.90
- EPS
- AARD N/A
- RGCO 1.32
- Revenue
- AARD N/A
- RGCO $94,120,500.00
- Revenue This Year
- AARD N/A
- RGCO $14.48
- Revenue Next Year
- AARD N/A
- RGCO $2.11
- P/E Ratio
- AARD N/A
- RGCO $16.48
- Revenue Growth
- AARD N/A
- RGCO 12.04
- 52 Week Low
- AARD $4.88
- RGCO $19.06
- 52 Week High
- AARD $19.58
- RGCO $24.20
- Technical
- Relative Strength Index (RSI)
- AARD 79.19
- RGCO 41.52
- Support Level
- AARD $10.75
- RGCO $22.25
- Resistance Level
- AARD $14.32
- RGCO $22.83
- Average True Range (ATR)
- AARD 1.07
- RGCO 0.50
- MACD
- AARD 0.58
- RGCO -0.10
- Stochastic Oscillator
- AARD 95.99
- RGCO 0.00
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About RGCO RGC Resources Inc.
RGC Resources Inc is involved in the business of distribution and sale of natural gas to residential, commercial, and industrial customers within its service territory in Roanoke, Virginia, and its surrounding localities. The company also provides certain non-regulated services. The company relies on multiple interstate pipelines to transport natural gas. The company operates in three segments: Gas Utility, which is the key revenue generator; Investment in Affiliates this segment reflects the income generated through the activities of the Company's investment in MVP and Southgate projects and Parent & Other including the unregulated activities of the Company as well as certain corporate eliminations.